-

Beta Bionics 96 Hour Deadline Alert: Kahn Swick & Foti, LLC Reminds Investors With Losses In Excess Of $100,000 of Deadline in Class Action Lawsuit Against Beta Bionics, Inc. - BBNX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until November 3, 2026 to file lead plaintiff applications in a securities class action lawsuit against Beta Bionics, Inc. (“Beta Bionics” or the “Company”) (NasdaqGM: BBNX), if they purchased or otherwise acquired Beta Bionics common stock between July 30, 2025 and February 24, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Central District of California.

What You May Do

If you purchased shares of Beta Bionics as above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-833-538-3615 or via email (lewis.kahn@ksfcounsel.com), or visit https://www.ksfcounsel.com/cases/nasdaqgm-bbnx/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by November 3, 2026.

About the Lawsuit

According to the Complaint, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects.

Specifically, the lawsuit alleges that Defendants failed to disclose to investors that: (i) the Company’s sole commercialized device, the iLet Bionic Pancreas insulin pump (“iLet”), employed an aggressive automated dosing algorithm that malfunctioned and delivered dangerously high levels of insulin, causing hypoglycemic events, including hundreds of life-threatening events requiring medical intervention and hospitalization; (ii) the Company had received thousands of related customer complaints that it failed to investigate or timely report to the U.S. Food and Drug Administration (“FDA”); (iii) the FDA Form 483 issued to the Company in June 2025 identified more than 18,000 unreported complaints and was not, as Defendants represented, limited to a minor difference in interpretation of which complaints were reportable; (iv) the Company had failed to implement meaningful corrective actions in response to the Form 483, resulting in an FDA warning letter concerning the Company’s quality management system, medical device reporting, and corrections and removals; and (v) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

The case is Holtzman v. Beta Bionics, Inc. et al., 26-cv-02612.

About Kahn Swick & Foti, LLC

KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.

TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services

To learn more about KSF, you may visit www.ksfcounsel.com.

CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-833-538-3615

Kahn Swick & Foti, LLC

NASDAQ:BBNX

Release Versions

Contacts

Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner
lewis.kahn@ksfcounsel.com
1-833-538-3615

Social Media Profiles
More News From Kahn Swick & Foti, LLC

Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Pacira BioSciences, Inc. (NasdaqGS: PCRX) to Viatris Inc. (NasdaqGS: VTRS). Under the terms of the proposed transaction, shareholders of Pacira will receive $36.50 in cash for each share of Pacira that they own. KSF is seeking to determine whether this consideration and the process that led to it are...

Blue Owl Technology Finance Corp. Securities Class Action Filed on Behalf of Former OTF II Shareholders Following Nearly 44% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., announce that a securities class action lawsuit has been filed against Blue Owl Technology Finance Corp. (NYSE: OTF) (“OTF” or the “Company”) on behalf of all former shareholders of Blue Owl Technology Finance Corp. II (“OTF II”) who received shares of OTF common stock in direct exchange for their OTF II shares in the March 24, 2025 merger by w...

Lumentum Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Lumentum Holdings Inc. - LITE

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Lumentum Holdings Inc. (NasdaqGS: LITE) to Marvell Technology, Inc. (NasdaqGS: MRVL). Under the terms of the proposed transaction, shareholders of Lumentum will receive 4.500 shares of Marvell common stock for each share of Lumentum that they own. KSF is seeking to determine whether this considerati...
Back to Newsroom